About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Interventions to Curb the Overuse of Acid-Suppressive Medications on an Inpatient General Medicine Service
A retrospective review was conducted to assess the effect of various interventions on inappropriate prescribing of acid-suppressive agents in the hospital. Providing educational lectures was helpful, but adding a pharmacist to the health care team resulted in the greatest decline in inappropriate use of these drugs.
Randolph E. Regal, BS, PharmD; Amanda D. Osta, MD; and Vikas I. Parekh, MD
Implications for Prescribing Practice and Therapeutic Interchange
Although low-molecular-weight heparins (LMWHs) have similar antithrombotic effects, they differ in their pharmacological and biochemical profiles. The authors discuss therapeutic interchange programs for currently available LMWHs and the risks to patients when agents are not clinically interchangeable.
Geno J. Merli, MD, and James B. Groce, PharmD
Drugs discussed include dasatinib (Sprycel), nilotinib (Tasigna), and imatinib (Gleevec) for patients with chronic myelogenous leukemia; deferasirox (Exjade) for beta-thalassemia major with iron overload; eculizumab (Soliris) for thrombocytopenia; and romiplostim (Nplate) for myelodysplastic syndromes.
Topics include an influenza vaccine (Fluzone High-Dose) to prevent virus subtypes A and B in older patients; von Willebrand factor/coagulation factor VIII complex (Wilate) to treat spontaneous and trauma-induced bleeding in patients with von Willebrand’s disease; and tranexamic acid (Lysteda) for heavy menstrual bleeding.
Marvin M. Goldenberg, PhD, RPh, MS
David B. Nash, MD, MBA, discusses the impact of health care reform on academic departments of medicine and their affiliated training programs.
David B. Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, explains how to ensure safety and minimize risks when oral tablets need to be split.
Matthew Grissinger, RPh, FASCP
Stephen Barlas discusses the FDA’s plans to simplify the labeling of consumer medical information.
From Actemra to Wilate, P&T presents the latest studies and information about FDA approvals, drug indications, product recalls, and industry updates.
Dr. Avena-Woods and Dr. Hilas review febuxostat (Uloric) for the treatment of gout.
Carmela Avena-Woods, PharmD, and Olga Hilas, PharmD, MPH, BCPS, CGP